Skip to main content

Advertisement

Figure 5 | BMC Biotechnology

Figure 5

From: Heterologous expression of human costimulatory molecule B7-2 and construction of B7-2 immobilized polyhydroxyalkanoate nanoparticles for use as an immune activation agent

Figure 5

Relative proliferation ratio of human peripheral blood lymphocytes by B7-2-PhaP immobilized PHBHHx nanoparticle treatment. Lymphocytes were seeded in triplicate at 1 × 104 cells per well in 96-well culture plates, followed by incubation with the indicated treatments for 72 h. 1: control cells; 2: cells treated with 5 μg ml-1 phytohemagglutinin; 3: cells treated with 500 ng ml-1 anti-CD3 antibody; 4: cells treated with 5 μg ml-1 PHBHHx nanoparticles; 5: cells treated with 1 μg ml-1 B7-2-PhaP fusion protein loaded PHBHHx nanoparticles; 6: cells treated with 1 μg ml-1 B7-2-PhaP fusion protein loaded PHBHHx nanoparticles plus 500 ng ml-1 anti-CD3 antibody; 7: cells treated with 1 μg ml-1 non-immobilized B7-2-PhaP fusion protein; 8: cells treated with 1 μg ml-1 non-immobilized B7-2-PhaP fusion protein plus 500 ng ml-1 anti-CD3 antibody. The cell proliferation was analyzed by MTT assay and the relative proliferation ratio was calculated relative to the cell proliferation level of the control group, which was defined as 100%.

Back to article page